Randomized double blind multicenter controlled clinical trial of fixed combination of benazepril and very low dose hydrochlorothiazide in the treatment of mild to moderate essential hypertension

Objective To evaluate the efficacy and safety of fixed-combination of benazepril and very low dose hydrochlorothiazide in the treatment of mild to moderate essential hypertension.Methods The multicenter, random samples ,double-blind, active-controlled study has been processed.The cases whose blood pressure treated by 10 mg per day benazepril single for 4 weeks were not to the target should be enered into two groups double-blindly,one group treated with fixed-combination of benazepril and very low dose hydrochlorothiazide(10 mg/12.5 mg),and another with benazepril(20 mg) only. The treatment period was 8 weeks.Results Compared with the control, trial group lowered sitting-blood pressure to 9.7 mm Hg (6.71%) of systolic presure and 8.71 mm Hg (9.41%) of diastolic presure after 8 weeks treatment. At the end of the treatment peroid, the total effective rate of fixed-combination of benazepril is 69.3%. The average T/P ratio of trial group is 74.38%.For the safety/tolerance, there are 19.13% incidences of adverse events regarded relatively with fixed-combination of benazepri. Most of them are cough.Conclusion Fixed-combination of benazepril (benazepril 10mg plus hydrochlorothiazide 12.5mg) administered once daily is well tolerated and reduces blood pressure in patients with mild to moderate hypertension.